<DOC>
	<DOC>NCT00127101</DOC>
	<brief_summary>This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients who have failed at least one prior systemic therapy.</brief_summary>
	<brief_title>An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Women or men greater than or equal to 18 years of age Advanced cutaneous Tcell lymphoma, stage IB or higher including Sezary Syndrome with progressive, persistent, or recurrent disease Failure of at least one systemic therapy, not including Bexarotene (Targretin) Eastern Cooperative Oncology Group (ECOG) status less than or equal to 2 (measurement to determine your ability to perform daily activities) Patient has had investigational treatment in the preceding 30 days Active hepatitis B or C, history of HIV Prior treatment with any HDAC inhibitor Patients must be disease free from prior malignancies for greater than 5 years, except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma insitu of the cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>